Document is current

Any future updates will be listed below

Sacituzumab govitecan plus pembrolizumab improves outcomes

Crossref DOI link: https://doi.org/10.1038/s41571-026-01129-y

Published Online: 2026-02-11

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark